1. Home
  2. TOPS vs PCSA Comparison

TOPS vs PCSA Comparison

Compare TOPS & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Ships Inc.

TOPS

TOP Ships Inc.

N/A

Current Price

$0.51

Market Cap

4.9M

ML Signal

N/A

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

N/A

Current Price

$1.27

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TOPS
PCSA
Founded
2000
2011
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
4.2M
IPO Year
2004
2012

Fundamental Metrics

Financial Performance
Metric
TOPS
PCSA
Price
$0.51
$1.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 3.3M
23.5K
Earning Date
09-16-2026
11-05-2026
Dividend Yield
★ 166.70%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $5,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.14
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.45
$0.11
52 Week High
$7.40
$8.88

Technical Indicators

Market Signals
Indicator
TOPS
PCSA
Relative Strength Index (RSI) 29.26 24.71
Support Level N/A N/A
Resistance Level $0.91 $2.33
Average True Range (ATR) 0.08 0.18
MACD -0.01 -0.04
Stochastic Oscillator 6.26 24.80

Price Performance

Historical Comparison
TOPS
PCSA

About TOPS TOP Ships Inc.

TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco-tanker vessels, focusing on the transportation of crude oil, petroleum products (both clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements. The company operates in two reportable segments: (i) the tanker segment and (ii) the megayacht segment.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

Share on Social Networks: